

Effect of circulating miR-126 levels on intracranial aneurysms and their predictive value for the rupture of aneurysms: A systematic review and meta-analysis

NIKOLAOS MATHIOUDAKIS¹, VASILIKI EPAMEINONDAS GEORGAKOPOULOU²,
KONSTANTINOS PATERAKIS³, PETROS PAPALEXIS^{4,5}, PAGONA SKLAPANI⁶,
NIKOLAOS TRAKAS⁶, DEMETRIOS A. SPANDIDOS⁷ and GEORGE FOTAKOPOULOS³

¹Department of Renal Transplantation, and ²Department of Infectious Diseases and COVID-19 Unit, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens; ³Department of Neurosurgery, General University Hospital of Larisa, 41221 Larisa; ⁴Unit of Endocrinology, First Department of Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens; ⁵Department of Biomedical Sciences, University of West Attica, 12243 Athens; ⁶Department of Biochemistry, Sismanogleio Hospital, 15126 Athens; ⁷Laboratory of Clinical Virology, School of Medicine, University of Crete, 71003 Heraklion, Greece

Received March 17, 2023; Accepted June 30, 2023

DOI: 10.3892/etm.2023.12110

Abstract. Intracranial aneurysm (IA) is a common cerebrovascular disease with a high risk of rupture. At present, the mechanisms underlying the formation and rupture of IAs is not clinically clear. MicroRNAs (miRNAs/miRs) are involved in the development of IAs. The present study aimed to determine the efficacy of circulating miRNA-126 (miR-126) levels as potential biomarkers for predicting aneurysmal ruptures. The present study searched comparative articles involving circulating miR-126 levels and intracranial aneurysms through electronic databases from 1980 to February, 2023. Collected variables included the first author's name, covered study period, publication year, total number of patients and age, and number of males. We collected information about the expression levels of circulating miR-126 in serum. Three articles met the eligibility criteria. The total number of patients was 379 [226 with IA rupture and 153 with non-rupture or/+ controls (healthy)]. The circulating miR-126 can be used as a biomarker for predicting aneurysmal rupture. Interestingly, an aneurysmal size >10 mm was associated with an IA rupture.

Introduction

Intracranial aneurysm (IA) is a common cerebrovascular disease, and its rupture may lead to massive intracranial and subarachnoid hemorrhage (1). Therefore, patients who are at a high risk of aneurysm rupture need to be diagnosed at an early stage in order for this to be prevented or actively treated and to reduce severe complications.

However, even with different diagnostic procedures available for identifying and predicting the aneurysmal rupture (2,3), the majority of these patients have no evident clinical symptoms before the rupture occurs, and 16-65% consequently develop ischemia (2,4-6).

At present, the mechanisms responsible for the formation and rupture of IA are not yet clinically clear. Research has indicated that microRNAs (miRNAs/miRs) play a key role in processing the majority of proteins, can be identified in biological fluids, and may be potential early biomarkers for various cerebrovascular diseases (7,8).

It has been demonstrated that miRNAs are involved in the development of IAs (9). Although reports exist of protein biomarkers in IAs, including tumor necrosis factor receptor (TNFR)-1 and S100B (10,11), studies on circulating miRNAs as biomarkers for ruptured IAs are limited.

The present meta-analysis aimed to identify the circulating miRNA-126 (miR-126) in ruptured IAs and evaluate their potential function as biomarkers for predicting aneurysmal rupture.

Data and methods

Literature research strategy. The present study searched the comparative articles involving circulating miR-126 levels and IAs through electronic databases, including the Cochrane

Correspondence to: Dr George Fotakopoulos, Department of Neurosurgery, General University Hospital of Larisa, Mezourlo 1, 41221, Larisa, Greece
E-mail: gphotakop@yahoo.gr

Key words: aneurysm, microRNA-126, aneurysmal rupture, biomarker, hemorrhage

Library, MEDLINE (1980 to February, 2023), PubMed (1980 to February, 2023) and Embase (1980 to February, 2023). The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines were applied for establishing the study protocol and design. The keywords 'aneurysm and genes', 'microRNA' or 'miRNA' or 'miR-126', and 'intracranial aneurysm and miR-126' were used in the MeSH list.

Selection of studies. Two of the authors (GF and VEG) independently extracted data from the included articles, following the guidelines for the epidemiology of meta-analysis. The following essential information was obtained: The main authors, year of publication, total case number in the IA rupture and non-rupture or/+ controls (healthy individuals) groups, study type, outcome indicator, etc. The extracted data were input into a designed, standardized table according to the Cochrane Handbook. The flow of the study selection process is depicted in Fig. 1. When there is disagreement, another author with authority has the final say.

Inclusion and exclusion criteria. If an article satisfied the following population, intervention, comparison, outcomes and study (PICOS) design criteria, it was considered for inclusion in the present meta-analysis: i) Population: Limited to patients with IA rupture and non-rupture or/+ controls (healthy individuals); ii) intervention: The use of the expression levels of circulating miR-126 at the IA rupture and non-rupture or/+ controls (healthy individuals); iii) comparison: The expression levels of circulating miR-126 were compared between patients with IA rupture and non-rupture or/+ controls (healthy individuals); iv) The detailed data of these articles are presented in Table I. To avoid publication bias, the final aim was to collect a homogeneous pool of manuscripts, including articles that compare only two modalities: The expression levels of circulating miR-126 between patients with IA rupture and non-rupture or/+ controls (healthy individuals).

All prospective and retrospective studies that evaluated at least one of the two modalities were included. Editorials, reviews, case reports and articles focusing on the pediatric population, unrelated outcomes, co-morbidities, experimental techniques, or one of the two modalities from that article pool were excluded. In addition, in the case of mixed or unclear results, the data were included in either the IA rupture, the non-rupture, or/+ controls (healthy individuals) group. In addition, to determine the association with levels of circulating miR-126 between patients with IA rupture and non-rupture or/+ controls (healthy individuals), information about the patient's age was collected. A body mass index (BMI) >22 kg/m², smoking, aneurysm location (anterior or posterior circulation); aneurysm size (<5, 5-10 and >10 mm); and the expression levels of circulating miR-126 >5 were detected in different time periods from 3 to 14 days. The expression levels of circulating miR-126 reported by the included articles were assessed after the IA rupture or in non-rupture or/+ controls (healthy individuals). Additionally, to decrease the risk of bias in the included articles, a quality assessment tool [the Newcastle-Ottawa Scale (NOS)] was used (Table II) (12).

Procedure for determining circulating miR-126 levels. As previously described (14-16), plasma was selected at a range of time points (1, 3, 7 and 14 days post-event) from each patient with IA rupture and from each patient with non-rupture or/+ controls (healthy individuals) (fasting state). All plasma samples were extracted from ethylene-diamine-tetra-acetic acid (EDTA) tubes and centrifuged as previously described (14-16). The serum miR-126 levels were examined using reverse transcription-quantitative PCR (RT-qPCR). Fasting venous blood (5 ml) was drawn from subjects [in the research group (RG)] on the first day after admission and 1 week after surgery, and in [the control group (CG)] during the morning physical examination], and then centrifuged for 10 min at 1,500 x g and 4°C. The supernatant was obtained in the refrigerator at -80°C for preservation. Total RNA in serum (200 µl) was extracted using TRIzol reagent, and the concentration and purity of the RNA solution were examined using a Nanodrop spectrophotometer. The OD260/OD280 was between 1.8 and 2.1. The total RNA was applied as a template, and cDNA was synthesized by reverse transcription. The total reaction system of RT-qPCR was 20 µl, including template cDNA (1 µl), Taq polymerase (0.2 µl), forward primer and reverse primer (each 1 µl), 2X SYBR-Green mix (1 µl), 20 mmol/l dNTPs (1 µl). Finally, the RNase-free water was supplemented to 20 µl. The reaction conditions were 95°C for 2 min, 95°C for 15 sec, 60°C for 30 sec, and 70°C for 10 sec, for a total of 40 cycles. The forward primer of miR-126 was 5'-ACACTCCAGCTGGGTCGTACCGTGAGTAAT-3', and the reverse primer was 5'-CTCAACTGGTGTCGTGGA GTCGGCAATTCAGTTGAGCGCATTAT-3'. The forward primer of internal reference gene U6 was 5'-CTCGCTTCG GCAGCAC-3', and the reverse primer was 3'-AACGCT TCACGAATTTGCGT-5'. The results were represented by the relative quantitative method and calculated using the 2^{-ΔΔCt} method. The RT-qPCR protocol does not correspond to any analysis performed during the present study (14-16). The RT-qPCR protocol described herein is related to the included articles which constitute the article pool of the present meta-analysis. Thus, this protocol is described herein in order to present the procedure for determining circulating miR-126 levels used in the included articles.

Evaluation of the risk of bias. The Cochrane Collaboration tool was used to assess the risk of bias and was used by two authors (GF and VEG) for each study (13). The evaluation included random sequence generation, allocation concealment, the blinding of participants and assessors, the blinding of outcome assessment, incomplete outcome data, selective reporting and other biases. The assessment results were classified into three levels: Low risk, high risk and unclear risk. A third author was designated to arbitrate any disagreements.

Statistical analysis and assessment of heterogeneity. All analyses were carried out using Review Manager Software (RevMan), version 5.4. Heterogeneity across trials was identified using I² statistics; considering I² >50% as high heterogeneity, a meta-analysis was conducted using a random-effect model according to the Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0). Otherwise, the fixed-effect model was performed. The




Figure 1. Flow chart of the study selection process.

continuous outcomes were expressed as a weighted mean difference with 95% confidence intervals (CIs). For discontinuous variables, odds ratios (OR) with 95% CIs were applied for the assessment. A P-value <0.05 was considered to indicate a statistically significant difference.

Results

Included studies. In total, three articles (14-16) fulfilled the eligibility requirements. The total number of patients was 379 [226 with IA rupture and 153 with non-rupture or/+ controls (healthy individuals)]. The study sample was based on three studies (Table I). Of these three studies, two were retrospective and one was prospective.

Epidemiological and clinical features. The mean age of the patients was 52.1 (52.7 years for the IA rupture sample and 51.5 years for the non-rupture or/+ controls (healthy individuals sample). The male-to-female ratio was 1:1.9 (Table I).

Age. Information regarding age was available in three articles (14-16). No significant difference in age was observed between the patients with IA rupture and the non-rupture or/+ controls (healthy individuals) (OR, 1.14; 95% CI, -0.60 to 2.88; and P=0.20), but with heterogeneity (P=0.03 and I²=70%) (Fig. 2A). For testing the sensitivity, the 'leave out one' model was used and one study was removed at a time (Table III). No heterogeneity (P=0.49 and I²=0%) was achieved only after removing the article by Wu *et al* (14); again, no statistically

Table I. Design and baseline characteristics of the trials included in the present meta-analysis.

Author, year	Sample size		Mean age (mean ± SD)		No. of males		BMI (kg/m ²) >22		Smoking		Location: Anterior circulation		Location: Posterior circulation		Size: <5 mm		Size: 5-10 mm		Size: >10 mm		miR-126 expression >5		
	Exp	Cont	Exp	Cont	Exp	Cont	Exp	Cont	Exp	Cont	Exp	Cont	Exp	Cont	Exp	Cont	Exp	Cont	Exp	Cont	Exp	Cont	(Refs.)
Yang <i>et al</i> , 2020	79	23	53.6±4.9	52.8±4	30	11	39	5	43	7	58	12	39	17	23	4	17	2	80	23	80	23	(16)
Wu <i>et al</i> , 2021	62	47	54.3±5.1	51.4±4.7	23	22	NR	NR	25	19	26	0	32	0	26	0	4	0	19	8	19	8	(14)
Luo <i>et al</i> , 2022	85	83	50.3±3.9	50.3±3.9	45	42	42	40	NR	NR	NR	NR	0	0	0	0	0	0	33	22	33	22	(15)

Exp, experimental group; Cont, control group; miR, microRNA; NR, not reported; BMI, body mass index; SD, standard deviation.

significant difference was found (OR, 0.21; 95% CI, -0.80 to 1.22; P=0.68) (Fig. 2B). When examining the funnel plot of the same parameter, it was found that the study results without the study by Wu *et al* (14) displayed better dispersion, with a low publication bias (Fig. 2C and D).

BMI >22(kg/m²). As regards information on BMI, it was available in two articles (15,16). No significant difference was found between the groups (OR, 1.76; 95% CI, 0.55 to 5.67; P=0.34), but with heterogeneity (P=0.06 and I²=72%) (Table III and Fig. S1).

Smoking. Information regarding smoking was available in two articles (14,16). No significant difference was found between the IA rupture and non-rupture or/+ control (healthy) groups (OR, 1.57; 95% CI, 0.59 to 4.19; P=0.37), but with heterogeneity (P=0.12 and I²=60%) (Table III and Fig. S2).

Location

Anterior circulation. As regards anterior circulation, information was available in two articles (14,16). No significant difference was found between groups (OR, 9.99; 95% CI, 0.41-243.1; P=0.16) and with no heterogeneity (P<0.05 and I²=79%) (Table III and Fig. S3).

Posterior circulation. Information regarding posterior circulation was available in two articles (14,16). Again, no significant difference was found between the IA rupture and non-rupture or/+ control (healthy) groups (OR, 3.09; 95% CI, 0.04 to 256.6; P=0.57), but with heterogeneity (P<0.05 and I²=93%) (Table III and Fig. S4).

Aneurysm size

<5 mm. As regards an aneurysm size <5 mm, information was available in two articles (14,16). No significant difference was found between groups (OR, 5.03; 95% CI, 0.02 to 1310.1; P=0.57) with no heterogeneity (P<0.05 and I²=93%) (Table III and Fig. S5).

5-10 mm. Information regarding an aneurysm size 5-10 mm was available in two articles (14,16). No significant difference was found between the IA rupture and non-rupture or/+ control (healthy) groups (OR, 9.11; 95% CI, 0.29 to 290.4; P=0.21), but with heterogeneity (P<0.05 and I²=81%) (Table III and Fig. S6).

>10 mm. As regards an aneurysm size >10 mm, information was available in two articles (14,16) and this demonstrated a statistically significant result (OR, 3.52; 95% CI, 0.90 to 13.8; P<0.05), with no heterogeneity (P=0.58; I²=0%) (Table III and Fig. 3). An aneurysm size >10 mm was found in 21 of 141 (14.8%) patients diagnosed with an IA ruptured aneurysm and in 2 of 70 (2.8%) non-rupture or/+ control (healthy) patients. When examining the funnel plot of the same parameter, no publication bias was found.

miR-126 expression >5. Information regarding miR-126 expression was available in three articles (14-16) and this demonstrated a statistical result (OR, 1.88; 95% CI, 1.10-3.21; P<0.05) with no heterogeneity (P=0.73 and I²=0%) (Table III and Fig. 4). A miR-126 expression >5 was found in 132 of 226 (58.4%) patients diagnosed with IA ruptured aneurysms and in 53 of 153 (34.6%) non-rupture or/+ controls (healthy) patients.

Table II. Newcastle-Ottawa Scale (NOS) quality assessment of final article pool.

Author, year	Study design	Newcastle-Ottawa Scale				Total scores	(Refs.)
		Selection	Comparability	Exposure			
Yang <i>et al</i> , 2020	Prosp	3	3	3		9	(16)
Wu <i>et al</i> , 2021	Prosp	3	3	3		9	(14)
Luo <i>et al</i> , 2022	Retro	3	2	2		7	(15)

Retro, retrospective; prosp, prospective.




Figure 2. (A) Forest plot for age: The results demonstrate no statistically significant difference groups (OR, 1.14; 95% CI, -0.60 to 2.88; P=0.20). (B) Forest plot for age without the study by Wu *et al* (14). The results again demonstrate no statistically significant difference (OR, 0.21; 95% CI, -0.80 to 1.22; P=0.68). (C and D) Funnel plots of the age between groups, with (left) or without (right) Wu *et al* (14), and with (left) heterogeneity (P=0.03 and I²=70%) or without (right) heterogeneity (P=0.49 and I²=0%). The studies depicted are as follows: Wu *et al* (14), Luo *et al* (15) and Yang *et al* (16). I², the percentage of total variation across studies that is due to heterogeneity rather than chance; CI, confidence interval; P, P-value; OR, odds ratio.

When examining the funnel plot of the same parameter, no publication bias was found.

Discussion

The present study suggests that the circulating miR-126 levels may be used as a biomarker for predicting aneurysmal rupture. More precisely, a *miR-126 expression* >5 was the

only statistically significant parameter related to IA bleeding compared with non-rupture or/+ control (healthy) patients. Of note, an aneurysmal size >10 mm was also associated with an IA rupture.

miRNAs constitute a varied class of small (18-25 nucleotides in length) non-coding RNA molecules (17). miRNAs balance numerous genes, various biological pathways and regulatory networks inside cells by unifying various regulatory

Table III. Parameters for the results of the meta-analysis.

Parameter	'Leave out one' model	Trial, n=3	Groups		Overall effect			Heterogeneity	
			Exper	Control	Effect estimate	95% CI	P-value	I ² (%)	P-value
Age (years)	-	3	226	153	1.14	(-0.60-2.88)	0.20	70	<0.05
	Yang <i>et al</i> , 2020 (16)	2	147	130	1.36	(-1.48-4.20)	0.35	85	<0.05
	Wu <i>et al</i> , 2021 (14)	2	164	106	0.21	(-0.80-1.22)	0.68	0	0.49
	Luo <i>et al</i> , 2022 (15)	2	141	70	1.88	(-0.18-3.93)	0.07	57	0.13
Sex (male)	-	3	98	75	0.85	(0.56-1.30)	0.46	0	0.52
BMI (kg/m ²) >22	-	2	81	45	1.76	(0.55-5.67)	0.34	72	0.06
Alcohol use	-	2	43	37	0.88	(0.51-1.52)	0.64	0	0.33
Smoking	-	2	68	26	1.57	(0.59-4.19)	0.37	60	0.12
Location									
Anterior circulation		2	84	12	9.99	(0.41-243.1)	0.16	79	<0.05
Posterior circulation		2	38	11	3.09	(0.04-256.6)	0.62	89	<0.05
Size									
<5 mm		2	71	17	5.03	(0.02-1310.1)	0.57	93	<0.05
5-10 mm	-	2	49	4	9.11	(0.29-290.4)	0.21	81	0.02
>10 mm	-	2	21	2	3.52	(0.90-13.85)	<0.05	0	0.58
miR-126		3	132	53	1.88	(1.10-3.21)	<0.05	0	0.73

Exper, experimental; miR, microRNA; BMI, body mass index; I², the percentage of total variation across studies that is due to heterogeneity rather than chance; CI, confidence interval.




Figure 3. (A) Forest plot for an aneurysm size >10 mm: The results demonstrated a statistically significant results (OR, 3.52; 95% CI, 0.90 to 13.85; P<0.05). (B) Funnel plot of the same parameter, demonstrating no heterogeneity (P=0.58 and I²=0%). The studies depicted are as follows: Wu *et al* (14) and Yang *et al* (16). I², the percentage of total variation across studies that is due to heterogeneity rather than chance; CI, confidence interval; P, P-value; OR, odds ratio.




Figure 4. (A) Forest plot for miR-126 expression >5: The results demonstrated a statistically significant result (OR, 1.88; 95% CI, 1.10 to 3.21; P<0.05). (B) Funnel plot of the same parameter, demonstrating no heterogeneity (P=0.73 and I²=0%). The studies depicted are as follows: Wu *et al* (14), Luo *et al* (15) and Yang *et al* (16). I², the percentage of total variation across studies that is due to heterogeneity rather than chance; CI, confidence interval; P, P-value; OR, odds ratio.

mechanisms, whether in a type of transcriptional input or by their operating regulatory output on different pathways (18). Defects in miRNA regulation may often impair cellular and biological activity and, ultimately, contribute to disease progression. Since miRNAs are involved in disease evolution, circulating miRNAs have potential diagnostic value (19). The miR-126 gene is located on human chromosome 9 and is mostly expressed in vascular endothelial cells. Mature miR-126 controls the propagation of vascular endothelial cells (20). In the present study, the expression of serum miR-126 was higher in patients with IA rupture compared with non-rupture or/+ control (healthy) patients.

Circulating miR-126 levels have been formerly established to be increased in the serum of patients with unruptured IAs compared to healthy controls (16). However, further analysis has indicated that levels of circulating miR-126 can be increased in several pathways, such as erythroblastic leukemia viral oncogene homolog signaling and mitogen-activated protein kinase signaling pathways, which are related to IA, but have higher levels in ruptured IAs compared with unruptured IAs. Thus, the present meta-analysis included a miR-126 level of expression >5 to evaluate its potential role as a biomarker for predicting aneurysmal ruptures.

The underlying mechanisms responsible for the creation, enlargement and rupture of IAs are complex. It is considered that under conditions of continuous hemodynamic pressure, the cerebral artery walls turn fragile and becomes unable to resist these types of pressure, and structural modifications and pathological development are conducted in these walls. Therefore, intimal hyperplasia and the appearance of blood clots serve to distinguish the barriers of unruptured aneurysms (21).

Some researchers have reported that larger aneurysms are significantly associated with an increased risk of rupture (22). Although the difference in size between the ruptured and unruptured aneurysms decreases with an increasing age, the mean size of all ruptured aneurysms is significantly larger than the mean size of unruptured aneurysms (23). However, although size is one of the strongest predictors, small aneurysms often rupture (24,25). In the present meta-analysis, an aneurysmal size >10 mm was associated with an IA rupture.

The present study has several limitations however, which should be mentioned. The expression levels of circulating miR-126 were detected over a different time period of 3-14 days, and the value of miR-126 in the prognosis of patients remains uncertain. In addition, the possible association between aneurysm size and other parameters such as C-protein, and the association between miR-126 and varying degrees of severity of vasospasm and the small sample size constitute the main limitation of the present study.

In conclusion, the present study proposes that the circulating miR-126 levels may be used as biomarkers for predicting aneurysmal ruptures. The change in the circulating levels of miR-126 in plasma between patients with IA bleeding and non-rupture or/+ controls (healthy) may have a marked effect on IA ruptures. Furthermore, an aneurysmal size >10 mm in patients with unruptured aneurysms is associated with a high risk of bleeding and may thus help physicians confirm the level of therapy accordingly. Future studies are required to examine the circulating levels of miR-126, which were recognized in

the present study as a potential biomarker for IA rupture. These levels may be relevant as a diagnostic tool in clinical practice for distinguishing between patients with severe and mild vasospasm.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

GF and VEG conceptualized the study. VEG, PS, GF, NM, PP, KP, DAS and NT analyzed the data, and wrote and prepared the draft of the manuscript. VEG and GF provided critical revisions. All authors contributed to manuscript revision, and have read and approved the final version of the manuscript. VEG and GF confirm the authenticity of all the raw data.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

DAS is the Editor-in-Chief for the journal, but had no personal involvement in the reviewing process, or any influence in terms of adjudicating on the final decision, for this article. The other authors declare that they have no competing interests.

References

- Han H, Guo S, Jiang H and Wu X: Feasibility and efficacy of enhanced recovery after surgery protocol in Chinese elderly patients with intracranial aneurysm. *Clin Interv Aging* 14: 203-207, 2019.
- Tsolaki V, Aravantinou-Fatorou A, Georgakopoulou VE, Spandidos DA, Papalexis P, Mathioudakis N, Tarantinos K, Trakas N, Sklapani P and Fotakopoulos G: Early diagnosis of cerebral vasospasm associated with cerebral ischemia following subarachnoid hemorrhage: Evaluation of computed tomography perfusion and transcranial doppler as accurate methods. *Med Int (Lond)* 2: 34, 2022.
- Fotakopoulos G, Makris D, Kotlia P, Kapsalaki E, Papanikolaou J, Georgiadis I, Zakynthinos E and Fountas K: The value of computed tomography perfusion & transcranial doppler in early diagnosis of cerebral vasospasm in aneurysmal & traumatic subarachnoid hemorrhage. *Future Sci OA* 4: FSO313, 2018.
- Ko NU, Rajendran P, Kim H, Rutkowski M, Pawlikowska L, Kwok PY, Higashida RT, Lawton MT, Smith WS, Zaroff JG and Young WL: Endothelial nitric oxide synthase polymorphism (-786T>C) and increased risk of angiographic vasospasm after aneurysmal subarachnoid hemorrhage. *Stroke* 39: 1103-1108, 2008.

5. Dumont AS, Dumont RJ, Chow MM, Lin CL, Calisaneller T, Ley KF, Kassell NF and Lee KS: Cerebral vasospasm after subarachnoid hemorrhage: Putative role of inflammation. *Neurosurgery* 53: 123-135, 2003.
6. Starke RM, Kim GH, Komotar RJ, Hickman ZL, Black EM, Rosales MB, Kellner CP, Hahn DK, Otten ML, Edwards J, *et al*: Endothelial nitric oxide synthase gene single-nucleotide polymorphism predicts cerebral vasospasm after aneurysmal subarachnoid hemorrhage. *J Cereb Blood Flow Metab* 28: 1204-1211, 2008.
7. Tsai PC, Liao YC, Wang YS, Lin HF, Lin RT and Juo SHH: Serum microRNA-21 and microRNA-221 as potential biomarkers for cerebrovascular disease. *J Vasc Res* 50: 346-354, 2013.
8. Fotakopoulos G, Georgakopoulou VE, Spandidos DA, Papalexis P, Angelopoulou E, Aravantinou-Fatorou A, Trakas N, Trakas I and Brotis AG: Role of miR-200 family in brain metastases: A systematic review. *Mol Clin Oncol* 18: 15, 2023.
9. Meeuwsen JAL, van T Hof FNG, van Rheenen W, Rinkel GJE, Veldink JH and Ruigrok YM: Circulating microRNAs in patients with intracranial aneurysms. *PLoS One* 12: e0176558, 2017.
10. de Torres R, Mancha F, Bustamante A, Canhao P, Fragata I and Montaner J: Usefulness of TNFR1 as biomarker of intracranial aneurysm in patients with spontaneous subarachnoid hemorrhage. *Future Sci OA* 6: FSO431, 2019.
11. Jung CS, Lange B, Zimmermann M, Seifert V: CSF and serum biomarkers focusing on cerebral vasospasm and ischemia after subarachnoid hemorrhage. *Stroke Res Treat* 2013: 560305, 2013.
12. Wells GA, Shea B, O'Connell D, *et al*: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, 2014. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
13. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, *et al*: The cochrane collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 343: d5928, 2011.
14. Wu J, Gareev I, Beylerli O, Mukhamedzyanov A, Pavlov V, Khasanov D and Khasanova G: Circulating miR-126 as a potential non-invasive biomarker for intracranial aneurysmal rupture: A pilot study. *Curr Neurovasc Res* 18: 525-534, 2021.
15. Luo J, Zhu X, Liu F, Zhao L, Sun Z, Li Y, Ye L and Li W: Expression of serum miR-126 in patients with intracranial aneurysm and its relationship with postoperative cerebral vasospasm. *Am J Transl Res* 14: 4372-4379, 2022.
16. Yang F, Xing WW, Shen DW, Tong MF and Xie FM: Effect of miR-126 on intracranial aneurysms and its predictive value for rupture of aneurysms. *Eur Rev Med Pharmacol Sci* 24: 3245-3253, 2020.
17. O'Brien J, Hayder H, Zayed Y and Peng C: Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. *Front Endocrinol (Lausanne)* 9: 402, 2018.
18. Fernández-Hernando C and Moore KJ: MicroRNA modulation of cholesterol homeostasis. *Arterioscler Thromb Vasc Biol* 31: 2378-2382, 2011.
19. Supriya M, Christopher R, Indira Devi B, Bhat DI and Shukla D: Circulating MicroRNAs as potential molecular biomarkers for intracranial aneurysmal rupture. *Mol Diagn Ther* 24: 351-364, 2020.
20. Liu D, Han L, Wu X, Yang X, Zhang Q and Jiang F: Genome-wide microRNA changes in human intracranial aneurysms. *BMC Neurol* 14: 188, 2014.
21. Fukuda M and Aoki T: Molecular basis for intracranial aneurysm formation. *Acta Neurochir Suppl* 120: 13-15, 2015.
22. Nguyen TN, Hoh BL, Amin-Hanjani S, Pryor JC, Ogilvy CS: Comparison of ruptured vs unruptured aneurysms in recanalization after coil embolization. *Surg Neurol* 68: 19-23, 2007.
23. Weir B, Disney L and Karrison T: Sizes of ruptured and unruptured aneurysms in relation to their sites and the ages of patients. *J Neurosurg* 96: 64-70, 2002.
24. Rinaldo L, Nesvick CL, Rabinstein AA and Lanzino G: Differences in size between unruptured and ruptured saccular intracranial aneurysms by location. *World Neurosurg* 133: e828-e834, 2020.
25. Kim BJ, Kang HG, Kwun BD, Ahn JS, Lee J, Lee SH, Kang DW, Kim JS and Kwon SU: Small versus large ruptured intracranial aneurysm: Concerns with the site of aneurysm. *Cerebrovasc Dis* 43: 139-144, 2017.



Copyright © 2023 Mathioudakis et al. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.